Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
Clinical trial NCT04974047 · COMPLETED
Trial details
- NCT number
- NCT04974047
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-17
- Primary completion
- 2023-04-17
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.